Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Balstilimab + Botensilimab + Poly ICLC + Pooled Mutant KRAS-Targeted Long Peptide Vaccine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Balstilimab | AGEN-2034|AGEN2034 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086). | |
Botensilimab | AGEN1181|AGEN 1181|AGEN-1181 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Botensilimab (AGEN1181) is an antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). | |
Poly ICLC | Hiltonol | Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373). | ||
Pooled Mutant KRAS-Targeted Long Peptide Vaccine | KRAS Peptide Vaccine | KRAS Inhibitor 18 | Pooled mutant KRAS-targeted long peptide vaccine is a mixture of long tumor-specific mutant KRAS peptides, which potentially induces a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KRAS (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): CT036). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06411691 | Phase I | Balstilimab + Botensilimab + Poly ICLC + Pooled Mutant KRAS-Targeted Long Peptide Vaccine | KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | Recruiting | USA | 0 |